Skip to main navigation
Skip to search
Skip to main content
Region Zealand Home
Help & FAQ
Link opens in a new tab
Dansk
English
Search content at Region Zealand
Home
Profiles
Research units
Projects
Research output
Prizes
Activities
Courses
Press/Media
Impacts
Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome
Anne Line Engsbro
*
, C. Rune Stensvold
, Henrik V. Nielsen
, Peter Bytzer
*
Corresponding author for this work
Medicine (Køge)
Research output
:
Contribution to journal
›
Article
›
Research
›
peer-review
Overview
Fingerprint
Fingerprint
Explore the research areas of 'Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome'.
Sort by
Weight
Alphabetically
Keyphrases
Irritable Bowel Syndrome
100%
Dientamoeba Fragilis
100%
Metronidazole
66%
Clinical Response
33%
Microbial Response
33%
Effective Treatment
16%
Tetracycline
16%
Logistic Regression Analysis
16%
Adequate Relief
16%
Simple Association
16%
Pharmacology, Toxicology and Pharmaceutical Science
Irritable Colon
100%
Dientamoeba
100%
Metronidazole
66%
Prevalence
16%
Infection
16%
Tetracycline
16%
Immunology and Microbiology
Dientamoeba fragilis
100%
Prevalence
50%
Agricultural and Biological Sciences
Metronidazole
100%
Case Study
25%
Tetracycline
25%